altxrtr t1_j7k0mnj wrote on February 7, 2023 at 10:19 AM Reply to comment by Call_In_The_Bin in Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study by burtzev Nope, Cassava Sciences’ simufilam has been shown to improve cognition, behavior and a range of biomarkers in mild AD patients. Currently in Phase 3. Permalink Parent 1
altxrtr t1_j7k0mnj wrote
Reply to comment by Call_In_The_Bin in Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study by burtzev
Nope, Cassava Sciences’ simufilam has been shown to improve cognition, behavior and a range of biomarkers in mild AD patients. Currently in Phase 3.